Davie C A, Barker G J, Thompson A J, Tofts P S, McDonald W I, Miller D H
NMR Research Unit, Institute of Neurology, London, UK.
J Neurol Neurosurg Psychiatry. 1997 Dec;63(6):736-42. doi: 10.1136/jnnp.63.6.736.
To test the hypothesis that irrecoverable neurological deficit in multiple sclerosis is associated with axonal loss.
1H magnetic resonance spectroscopy (MRS) was carried out in a group of patients with clinically definite multiple sclerosis (n=31). Using this technique, the apparent concentration of NA ([NA] the sum of N-acetyl aspartate (NAA), a neuronal marker, and N-acetylaspartylglutamate has been compared in four groups of patients with multiple sclerosis classified as relapsing-remitting, secondary progressive, primary progressive, benign, and a control group.
In the patients with relapsing-remitting disease (n=9) there was a highly significant reduction of apparent NA (median 8.73 mM, range 6.86 mM-10.74 mM, P=0.0008) from an area of high signal compared with the control group (median 11.97 mM, range 10.55 mM-14.5 mM). In the patients with secondary progressive disease (n=10), there was again a highly significant reduction of apparent NA (median 7.82 mM, range 3.5 mM-10.3 mM, P=0.0003) from an area of high signal compared with the control group. In the patients with primary progressive disease (n=6) there was once again a highly significant reduction of apparent NA (median 8.83 mM, range 6.95 mM-9.89 mM, P<0.002) from an area of high signal compared with the control group. In the patients with benign disease, however, there was no significant difference in the apparent NA (median 10.5 mM, range 8.53 mM-12.8 mM, P>0.05) from an area of high signal compared with the control group. In the patients with benign disease (n=5) there was also no significant difference in the apparent NA (median 10.74 mM, range 8.58 mM-13.4 mM, P>0.3) from an area of normal appearing white matter compared with the control group. In the patients with primary progressive disease, however, there was a significant reduction of apparent NA from an area of normal appearing white matter (median 8.78 mM, range 8.7 mM-12.38 mM, P< 0.025) compared with the control group. There was a significant inverse correlation between [NA] from lesions in the patients with multiple sclerosis and disability as measured on the Kurtzke expanded disability scale score (r= -0.364, 0.05>P>0.02).
These findings support the hypothesis that axonal loss is important in the development of disability in multiple sclerosis. They also provide evidence for axonal loss in normal appearing white matter in patients with primary progressive disease.
检验多发性硬化症中不可恢复的神经功能缺损与轴突损失相关这一假设。
对一组临床确诊的多发性硬化症患者(n = 31)进行氢质子磁共振波谱(MRS)检查。运用该技术,比较了复发缓解型、继发进展型、原发进展型、良性型四组多发性硬化症患者以及一个对照组中神经元标志物N - 乙酰天门冬氨酸(NAA)与N - 乙酰天门冬氨酰谷氨酸之和即NA的表观浓度。
复发缓解型疾病患者(n = 9)中,与对照组(中位数11.97 mM,范围10.55 mM - 14.5 mM)相比,高信号区域的表观NA显著降低(中位数8.73 mM,范围6.86 mM - 10.74 mM,P = 0.0008)。继发进展型疾病患者(n = 10)中,与对照组相比,高信号区域的表观NA再次显著降低(中位数7.82 mM,范围3.5 mM - 10.3 mM,P = 0.0003)。原发进展型疾病患者(n = 6)中,与对照组相比,高信号区域的表观NA再次显著降低(中位数8.83 mM,范围6.95 mM - 9.89 mM,P < 0.002)。然而,良性型疾病患者中,与对照组相比,高信号区域的表观NA无显著差异(中位数10.5 mM,范围8.53 mM - 12.8 mM,P > 0.05)。良性型疾病患者(n = 5)中,与对照组相比,正常白质区域的表观NA也无显著差异(中位数10.74 mM,范围8.58 mM - 13.4 mM,P > 0.3)。然而,原发进展型疾病患者中,与对照组相比,正常白质区域的表观NA显著降低(中位数8.78 mM,范围8.7 mM - 12.38 mM,P < 0.025)。多发性硬化症患者病灶处的NA与用Kurtzke扩展残疾量表评分衡量的残疾程度之间存在显著负相关(r = -0.364,0.05 > P > 0.02)。
这些发现支持轴突损失在多发性硬化症残疾发展过程中起重要作用这一假设。它们还为原发进展型疾病患者正常白质中的轴突损失提供了证据。